This French Biotech Just Secured $12.6M to Tackle Cold Tumors

Jan de Vries · 2026-07-22

### A Fresh Injection of Capital for a Bold Mission Brenus Pharma, a clinical-stage biotech based in Lyon, France, just announced an $12.6 million extension to its Series A round. That brings their total raised since launching in 2019 to a hefty $43.5 million. The company's goal? To stop cancer from coming back, especially in those hard-to-treat solid tumors where current therapies just don't cut it. This round wasn't just about the money. It signals serious confidence from both old and new backers. Existing investors like Angelor, UI Investissement, and Bpifrance doubled down. But the real headline here is the arrival of two international players: Sambrinvest and Korea Omega Investment Corp. That's a big deal for a French startup, showing their tech has global appeal. ### What Makes Brenus Pharma Different? You might be wondering, "Another cancer biotech? What's so special?" Well, here's the thing. About 85% of solid tumors are what scientists call "cold." That means the immune system doesn't recognize them as a threat. Most immunotherapies flop against these because they can't get the immune system to pay attention. Brenus built a platform that changes that. Their technology mimics the proteins tumors express, making them visible to the immune system. It's like turning on a spotlight in a dark room. The immune system can then mount a multi-specific response that adapts as the tumor evolves. Pretty clever, right? Unlike personalized therapies that require fiddling with a patient's own cells, Brenus's approach is "off-the-shelf." That means predictable supply chains and lower manufacturing costs. No patient-specific manipulation needed. That scalability could be a game-changer for bringing treatments to more people faster. ### The Lead Candidate: STC-1010 Their front-runner is STC-1010, a next-generation immunotherapy built on something called Stimulated Ghost Cells (SGC) technology. It's targeting metastatic colorectal cancer (mCRC), specifically the microsatellite stable (MSS) subtype. That's a tough nut to crack, and current options are limited. Just recently, the U.S. Food and Drug Administration (FDA) accepted their Investigational New Drug (IND) application for STC-1010. That means they can start Phase I trials in the United States. For a European startup, getting FDA green light is a massive milestone. It opens doors to the world's biggest pharmaceutical market. ### What This Funding Will Do CEO Paul Bravetti put it plainly: "This funding will enable us to complete the Phase I program and continue accelerating our in vivo immunotherapy platform." Translation: they're moving fast. The $12.6 million will push STC-1010 through early clinical testing and help develop their next drug candidate. Dae Kyeong Bae from Korea Omega Investment Corp. shared his enthusiasm: "We couldn't be more confident in our first investment in France. The company combines truly differentiated technology with early clinical validation and team executing at pace." That kind of endorsement from an international investor speaks volumes. ### The Bigger Picture Brenus is part of a wave of European biotechs proving they can compete on the global stage. With this funding, they're not just advancing a single drug. They're building a platform that could tackle multiple tumor types. If STC-1010 works, it could pave the way for a whole new class of immunotherapies. The company's approach is smart: combine deep multi-omics data, exclusive tumor-bank partnerships, and strong manufacturing know-how to mirror the complexity of real tumors. By engaging dendritic cells, they aim to convert cold tumors into hot ones, mobilizing the patient's own immune system against evolving cancer. For professionals watching the EU startup scene, this is one to keep an eye on. It's not every day a French biotech pulls in international investors and FDA acceptance in the same breath. The next few months will be critical as they start dosing patients in Phase I. If the data holds up, Brenus Pharma could be a name you hear a lot more of.